- Details
- Description
-
Packaging Size30c/Bottle
-
Strength15mg
-
CompositonGolidocitinib
-
TreatmentAdult patients with relapsed or refractory peripheral T-cell lymphoma (r/r PTCL)
-
FormCapsule
-
Brand高瑞哲
-
Quantity Unit0.15g*30c/Box
-
ManufacturerDizal Pharma, China
Golidocitinib (DZD4205) is currently the first and only Janus kinase 1 (JAK1) selective inhibitor being evaluated for the treatment of r/r PTCL. In June 2024, golidocitinib was approved by the National Medical Products Administration (NMPA) of China for the treatment of adult patients with relapsed or refractory peripheral T-cell lymphoma (r/r PTCL).
- Golidocitinib sold under the brand name 高瑞哲® in china.